Hormonal and histological evaluation of the luteal phase after combined GnRH-agonist/gonadotrophin treatment for superovulation and luteal phase support in in-vitro fertilization
- PMID: 1761657
- DOI: 10.1093/oxfordjournals.humrep.a137458
Hormonal and histological evaluation of the luteal phase after combined GnRH-agonist/gonadotrophin treatment for superovulation and luteal phase support in in-vitro fertilization
Abstract
A hormonal and histological study of the luteal phase was performed in 21 stimulated in-vitro fertilization (IVF) patients not undergoing embryo transfer. Ovarian stimulation was carried out with gonadotrophins [follicle stimulating hormone (FSH) + human menopausal gonadotrophin (HMG)] under pituitary suppression with buserelin. Ovulation was induced with 5000 IU human chorionic gonadotrophin (HCG) and additional doses of 5000, 2500 and 2500 IU were given on the day of follicular aspiration, and 2 and 5 days later respectively, to support the luteal phase. Supraphysiological levels of oestradiol (E2) and progesterone in plasma were found in the midluteal phase of all women, while prolactin was in the normal range. An endometrial biopsy taken in the late luteal phase was normal in 90.5% (19/21) of patients, most of them (15/19, 79%) having E2 greater than 1500 pg/ml on the day of HCG. Conversely, both patients with defective endometrial biopsies had E2 levels less than 1500 pg/ml.
Similar articles
-
Hormonal profiles in successful and unsuccessful implantation in IVF-ET after combined GnRH agonist/gonadotropin treatment for superovulation and hCG luteal support.Gynecol Endocrinol. 1995 Mar;9(1):51-8. doi: 10.3109/09513599509160191. Gynecol Endocrinol. 1995. PMID: 7793300 Clinical Trial.
-
Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.J Clin Endocrinol Metab. 2003 Sep;88(9):4186-92. doi: 10.1210/jc.2002-021953. J Clin Endocrinol Metab. 2003. PMID: 12970285 Clinical Trial.
-
Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.Hum Reprod. 2005 Jun;20(6):1541-7. doi: 10.1093/humrep/deh793. Epub 2005 Feb 10. Hum Reprod. 2005. PMID: 15705618
-
Superovulation strategy before in vitro fertilization.Clin Obstet Gynaecol. 1985 Sep;12(3):687-723. Clin Obstet Gynaecol. 1985. PMID: 3933880 Review.
-
Luteal phase defects in assisted reproduction: the role of luteal phase supplementation.Acta Eur Fertil. 1992 Jan-Feb;23(1):15-9. Acta Eur Fertil. 1992. PMID: 1293894 Review.
Cited by
-
Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction.J Assist Reprod Genet. 1994 Feb;11(2):74-8. doi: 10.1007/BF02215991. J Assist Reprod Genet. 1994. PMID: 7819706 Clinical Trial.
-
Influence of midluteal serum prolactin on outcome of pregnancy after IVF-ET: a preliminary study.J Assist Reprod Genet. 2001 Jul;18(7):387-90. doi: 10.1023/a:1016674523317. J Assist Reprod Genet. 2001. PMID: 11499323 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources